Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

INTERNATIONAL PHARMACEUTICALS' VINCRISTINE MARKETING APPROVAL

Executive Summary

INTERNATIONAL PHARMACEUTICALS' VINCRISTINE MARKETING APPROVAL was reportedly rescinded by FDA Dec. 2. FDA approved an ANDA for International's vincristine sulfate injection in 1 mg/ml, in 1 ml, 2 ml, and 5 ml vials on Nov. 26. Two days later, on Nov. 28, the agency received a patent certification from Lilly for its liquid vincristine product, Oncovin. Lilly was granted a formulation patent by the Patent and Trademark Office on Oct. 28. Lilly says the formulation patent gives it exclusive right to "make, use and sell the patented liquid formulations of vincristine sulfate" for 17 years. Two other firms have received approval for generic versions of liquid injectable vincristine, Par's Quad subsidiary in April and LyphoMed in September. The Quad and LyphoMed approvals were issued before Lilly was granted a patent. A patent infringement suit against Quad was filed the same day Lilly was granted its patent ("The Pink Sheet" Nov. 3, T&G-2). LyphoMed, in turn, filed suit against Lilly seeking to have Lilly's patent declared invalid. Adria also markets the vincristine formulation under a licensing agreement with Quad.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS011154

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel